1. Home
  2. CRSP vs CUZ Comparison

CRSP vs CUZ Comparison

Compare CRSP & CUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$54.47

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Logo Cousins Properties Incorporated

CUZ

Cousins Properties Incorporated

HOLD

Current Price

$28.44

Market Cap

4.7B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
CUZ
Founded
2013
1958
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.7B
IPO Year
2016
1994

Fundamental Metrics

Financial Performance
Metric
CRSP
CUZ
Price
$54.47
$28.44
Analyst Decision
Buy
Buy
Analyst Count
17
8
Target Price
$70.29
$28.00
AVG Volume (30 Days)
1.7M
1.7M
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
5.11%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,590,000.00
$993,816,000.00
Revenue This Year
$807.72
$5.61
Revenue Next Year
$172.52
$4.23
P/E Ratio
N/A
N/A
Revenue Growth
9169.85
16.00
52 Week Low
$44.12
$21.03
52 Week High
$78.48
$30.57

Technical Indicators

Market Signals
Indicator
CRSP
CUZ
Relative Strength Index (RSI) 55.94 60.34
Support Level $47.48 $28.03
Resistance Level $59.61 $29.62
Average True Range (ATR) 2.84 0.67
MACD 0.25 -0.08
Stochastic Oscillator 54.76 62.04

Price Performance

Historical Comparison
CRSP
CUZ

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About CUZ Cousins Properties Incorporated

Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.

Share on Social Networks: